Synlogic Reports Positive Top-Line Phase 1 Data Demonstrating Safety and Tolerability and Proof of Mechanism in Healthy Volunteers for SYNB1020, a Synthetic BioticTM Medicine for the Treatment of Hyperammonemia

Stock Information for Synlogic Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Synlogic Inc.

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
Synlogic Adopts Limited Duration Stockholders Rights Plan
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
Synlogic Provides Corporate Update and Outlook for 2024
Synlogic Announces Contract with the Air Force Research Lab
Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023
Sidoti Events, LLC's Virtual November Micro-Cap Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.